Replies to post #6824 on CytoSorbents Corporation (CTSO)

[pharmeng]

I agree. Without good sales, valuation pretty much dependent on clinical development and I think I've said enough about that.

The company has historically moved pretty slow, so I think Fresenius will take some more time to actually pick up.

The cardiac partner is also moving much slower than I thought. They are apparently only working with one physician, but no cytosorb use yet in 5 months?

[dah174174]

Based on your comments you better sell now and then you can buy it back at $6.25. My feeling is that a base is forming at the $8 to $8.50 level and it can be bought as a longer term investment. I have been buying back some of the shares I sold a few points higher.

[SABAI]

I agree and would go Even further by saying this will fall into low 5 or higher 4's in the next few months. This whole "regrouping of a New sales team" is a JOKE cos if you have a killer product they tear it of your hands. Cytosorb is well known in over 50 hospitals in Germany. They alone could generate easily 2,3 or 5M$ in sales for Q1. But they are not reordering or ordering more. Why??? Something smells here......is there info leaked about a failed trial or where is the problem???? All imo and not bashing to get in lower. Just looking for answers....gla